DOCSLIB.ORG

Supplemental Table 4. Expression of CX3CR1 in Specimens of Ovarian Cancer (Multiple Types)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 4. Expression of CX3CR1 in Specimens of Ovarian Cancer (Multiple Types) Supplemental Table 4. Expression of CX3CR1 in specimens of ovarian cancer (multiple types). Position Number Sex* Age* Organ* Pathology Diagnosis* Grade* Type* Intensity** Location Percentage*** Score**** 2 100 200 A1 1 F 38 Ovary Krukenberg tumor - Malignant cytoplasmic 1 80 80 A2 2 F 37 Ovary Krukenberg tumor - Malignant cytoplasmic 100 100 A3 3 F 30 Ovary Krukenberg tumor - Malignant 1 cytoplasmic 0 n/a 0 0 A4 4 F 35 Ovary Krukenberg tumor - Malignant 0 0 0 0 A5 5 F 54 Ovary Krukenberg tumor - Malignant 1.5 100 150 A6 6 F 54 Ovary Krukenberg tumor - Malignant cytoplasmic 3 100 300 A7 7 F 36 Ovary Krukenberg tumor - Malignant cytoplasmic 1 50 50 A8 8 F 49 Ovary Krukenberg tumor - Malignant cytoplasmic 3 90 270 A9 9 F 35 Ovary Krukenberg tumor - Malignant cytoplasmic 0 0 0 0 A10 10 F 36 Ovary Krukenberg tumor - Malignant 1 10 10 B1 11 F 65 Ovary Carcinosarcoma - Malignant cytoplasmic 2 70 140 B2 12 F 15 Ovary Yolk sac tumor - Malignant cytoplasmic 3 80 240 B3 13 F 27 Ovary Yolk sac tumor - Malignant cytoplasmic 2 80 160 B4 14 F 20 Ovary Yolk sac tumor - Malignant cytoplasmic 2.5 80 200 B5 15 F 14 Ovary Yolk sac tumor - Malignant cytoplasmic 0.5 20 10 B6 16 F 32 Ovary Yolk sac tumor - Malignant cytoplasmic 1.5 80 120 B7 17 F 22 Ovary Yolk sac tumor - Malignant cytoplasmic 1 10 10 B8 18 F 16 Ovary Yolk sac tumor - Malignant cytoplasmic 2 100 200 B9 19 F 15 Ovary Yolk sac tumor - Malignant cytoplasmic 3 100 300 B10 20 F 36 Ovary Dysgerminoma - Malignant cytoplasmic 1.5 70 105 C1 21 F 35 Ovary Dysgerminoma - Malignant cytoplasmic 1 80 80 C2 22 F 41 Ovary Dysgerminoma - Malignant cytoplasmic 1 80 80 C3 23 F 12 Ovary Dysgerminoma - Malignant cytoplasmic 2 100 200 C4 24 F 19 Ovary Dysgerminoma - Malignant cytoplasmic 1.5 100 150 C5 25 F 11 Ovary Dysgerminoma - Malignant cytoplasmic 1.5 80 120 C6 26 F 25 Ovary Dysgerminoma - Malignant cytoplasmic 1 50 50 C7 27 F 25 Ovary Dysgerminoma - Malignant cytoplasmic 0.5 30 15 C8 28 F 28 Ovary Mature teratoma - Benign cytoplasmic 0 0 0 0 C9 29 F 18 Ovary Mature teratoma - Benign 2.5 100 250 C10 30 F 16 Ovary Mature teratoma - Benign cytoplasmic Teratoma with malignant transformation (squamous 3 100 300 D1 31 F 50 Ovary cell carcinoma) - Malignant perinuclear 3 100 300 D2 32 F 30 Ovary Mature teratoma - Benign cytoplasmic 3 100 300 D3 33 F 30 Ovary Mature teratoma - Benign cytoplasmic D4 34 F 30 Ovary Mature teratoma - Benign not readable n/a n/a n/a Mature teratoma (ovarian D5 35 F 38 Ovary tissue sparse) - Benign not readable n/a n/a n/a 3 100 300 D6 36 F 22 Ovary Mature teratoma - Benign cytoplasmic 3 100 300 D7 37 F 27 Ovary Mature teratoma - Benign cytoplasmic D8 38 F 28 Ovary Mature teratoma - Benign not readable n/a n/a n/a 3 60 180 D9 39 F 24 Ovary Mature teratoma - Benign cytoplasmic 3 100 300 D10 40 F 33 Ovary Mature teratoma - Benign cytoplasmic Mature teratoma (ovarian 2 100 200 E1 41 F 37 Ovary tissue) - Benign cytoplasmic E2 42 F 39 Ovary Mature teratoma - Benign not readable n/a n/a n/a E3 43 F 48 Ovary Mature teratoma - Benign not readable n/a n/a n/a Mature teratoma (ovarian 1 100 100 E4 44 F 27 Ovary tissue) - Benign cytoplasmic 3 100 300 E5 45 F 54 Ovary Mature teratoma - Benign cytoplasmic E6 46 F 19 Ovary Mature teratoma (sparse) - Benign not readable n/a n/a n/a 2 100 200 E7 47 F 52 Ovary Mature teratoma - Benign cytoplasmic Sertoli-stromal cell tumor 3 60 180 E8 48 F 26 Ovary (sparse) 3 Malignant cytoplasmic 1.5 70 105 E9 49 F 59 Ovary Sertoli-stromal cell tumor 2 Malignant cytoplasmic 3 100 300 E10 50 F 60 Ovary Granular cell tumor - Malignant cytoplasmic 2.5 80 200 F1 51 F 44 Ovary Granular cell tumor - Malignant cytoplasmic 1 70 70 F2 52 F 63 Ovary Granular cell tumor - Malignant cytoplasmic 1.5 70 105 F3 53 F 60 Ovary Granular cell tumor - Malignant cytoplasmic 3 90 270 F4 54 F 60 Ovary Granular cell tumor - Malignant cytoplasmic 1.5 50 75 F5 55 F 54 Ovary Granular cell tumor - Malignant cytoplasmic 2 90 180 F6 56 F 65 Ovary Granular cell tumor - Malignant cytoplasmic 0 0 0 F7 57 F 33 Ovary Granular cell tumor - Malignant n/a 1 40 40 F8 58 F 31 Ovary Granular cell tumor - Malignant cytoplasmic 1.5 40 60 F9 59 F 66 Ovary Granular cell tumor - Malignant cytoplasmic 2 100 200 F10 60 F 51 Ovary Granular cell tumor - Malignant cytoplasmic 1 70 70 G1 61 F 49 Ovary Granular cell tumor - Malignant cytoplasmic 1 30 30 G2 62 F 40 Ovary Granular cell tumor - Malignant cytoplasmic 2.5 100 250 G3 63 F 50 Ovary Granular cell tumor - Malignant cytoplasmic 0 0 0 G4 64 F 19 Ovary Granular cell tumor - Malignant n/a 100 150 G5 65 F 37 Ovary Thecoma - Malignant 1.5 cytoplasmic 2 100 200 G6 66 F 60 Ovary Thecoma - Malignant cytoplasmic 3 70 210 G7 67 F 37 Ovary Thecoma - Malignant cytoplasmic 2 100 200 G8 68 F 46 Ovary Thecoma - Malignant cytoplasmic G9 69 F 56 Ovary Thecoma - Malignant not readable n/a n/a n/a 1 100 100 G10 70 F 71 Ovary Thecoma - Malignant cytoplasmic 1 100 100 H1 71 F 63 Ovary Thecoma - Malignant cytoplasmic 1.5 100 150 H2 72 F 66 Ovary Thecoma - Malignant cytoplasmic 1 15 15 H3 73 F 53 Ovary Thecoma - Malignant cytoplasmic 1 90 90 H4 74 F 20 Ovary Thecoma (sparse) - Malignant cytoplasmic 1 90 90 H5 75 F 15 Ovary Thecoma - Malignant cytoplasmic 1 100 100 H6 76 F 62 Ovary Thecoma - Malignant cytoplasmic 1.5 100 150 H7 77 F 45 Ovary Thecoma - Malignant cytoplasmic 1.5 80 120 H8 78 F 57 Ovary Thecoma - Malignant cytoplasmic 1.5 90 135 H9 79 F 66 Ovary Thecoma - Malignant cytoplasmic 1.5 70 105 H10 80 F 22 Ovary Gynandroblastoma - Malignant cytoplasmic Simple cyst (fibrous I1 81 F 29 Ovary tissue) - Cyst not readable n/a n/a n/a 3 100 300 I2 82 F 35 Ovary Leuteivic cyst - Cyst cytoplasmic I3 83 F 44 Ovary Cyst (ovarian tissue) - Cyst not readable n/a n/a n/a I4 84 F 35 Ovary Cyst (fibrofatty tissue) - Cyst not readable n/a n/a n/a I5 85 F 27 Ovary Cyst (fibrofatty tissue) - Cyst not readable n/a n/a n/a I6 86 F 35 Ovary Simple cyst - Cyst not readable n/a n/a n/a I7 87 F 42 Ovary Simple cyst (sparse) - Cyst not readable n/a n/a n/a I8 88 F 37 Ovary Simple cyst (sparse) - Cyst not readable n/a n/a n/a Cyst (fibrous tissue and I9 89 F 28 Ovary blood vessel) - Cyst not readable n/a n/a n/a 3 100 300 I10 90 F 27 Ovary Follicular cyst - Cyst cytoplasmic Cancer adjacent normal J1 91 F 35 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J2 92 F 23 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal ovarian tissue (fibrous J3 93 F 36 Ovary tissue and blood vessel) - Normal no epithelium n/a n/a n/a Cancer adjacent normal ovarian tissue (lutein J4 94 F 48 Ovary cyst) - Normal no epithelium n/a n/a n/a Cancer adjacent normal J5 95 F 51 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J6 96 F 40 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J7 97 F 24 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J8 98 F 39 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J9 99 F 39 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a Cancer adjacent normal J10 100 F 46 Ovary ovarian tissue - Normal no epithelium n/a n/a n/a * Information obtained from the manufacturer (US Biomax; Rockville, MD) as it pertains to the ovarian carcinoma metastasis tissue microarray OV1002; TMA slide contained singular cores of each case (total n=100) ** Intensity of staining was scored as negative (0), weak positive (1), moderate positive (2), and strong positive (3) *** Denotes percentage of positive cells in the core **** Score has been calculated as intensity multiplied by percentage of positive cells ***** In the specimens of normal ovary only ovarian surface epithelium was scored * Information obtained from the manufacturer (US Biomax; Rockville, MD) as it pertains to the ovarian carcinoma metastasis tissue microarray OV1002; TMA slide contained singular cores of each case (total n=100).
Load more

Recommended publications
  • A Rare Presentation of Benign Brenner Tumor of Ovary: a Case Report
    International Journal of Reproduction, Contraception, Obstetrics and Gynecology Periasamy S et al. Int J Reprod Contracept Obstet Gynecol. 2018 Jul;7(7):2971-2974 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20182920 Case Report A rare presentation of benign Brenner tumor of ovary: a case report Sumathi Periasamy1, Subha Sivagami Sengodan2*, Devipriya1, Anbarasi Pandian2 1Department of Surgery, 2Department of Obstetrics and Gynaecology, Government Mohan Kumaramangalam Medical College, Salem, Tamil Nadu, India Received: 17 April 2018 Accepted: 23 May 2018 *Correspondence: Dr. Subha Sivagami Sengodan, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Brenner tumors are rare ovarian tumors accounting for 2-3% of all ovarian neoplasms and about 2% of these tumors are borderline (proliferating) or malignant. These tumors are commonly seen in 4th-8th decades of life with a peak in late 40s and early 50s. Benign Brenner tumors are usually small, <2cm in diameter and often detected incidentally during surgery or on pathological examination. Authors report a case of a large, calcified benign Brenner tumor in a 55-year-old postmenopausal woman who presented with complaint of abdominal pain and mass in abdomen. Imaging revealed large complex solid cystic pelvic mass -peritoneal fibrosarcoma. She underwent laparotomy which revealed huge Brenner tumor weighing 9kg arising from left uterine cornual end extending up to epigastric region.
    [Show full text]
  • Malignant Fibrothecomatous Tumour of the Ovary
    868 J Clin Pathol 1998;51:868–871 Malignant fibrothecomatous tumour of the ovary: J Clin Pathol: first published as 10.1136/jcp.51.11.868 on 1 November 1998. Downloaded from diagnostic value of anti-inhibin immunostaining W G McCluggage, J M Sloan, D D Boyle, P G Toner Abstract ultrasound scan, which also revealed free fluid Malignant ovarian tumours of the fibro- in the pelvic cavity. Serum CA-125 was mark- thecoma group are rare. The clinico- edly raised at 196 U/ml. A presumptive pathological features of a case of ovarian diagnosis of ovarian cancer was made. At malignant fibrothecoma in which there laparotomy, tumour masses were present in the was metastatic disease in the small intes- right ovary and in the terminal ileum. There tine and peritoneum at presentation are were also multiple tumour nodules throughout described. A number of diVerential diag- the abdominal peritoneum. The clinical im- noses were considered but positive immu- pression was of a primary lesion in the right nohistochemical staining of the resected ovary, with small intestinal and peritoneal ovarian and small intestinal neoplasms metastases. Total abdominal hysterectomy and with anti-inhibin was of value in confirm- bilateral salpingo-oophorectomy was per- ing a sex cord–stromal tumour and in formed, together with resection of a length of excluding other lesions. The two tumours terminal ileum. The postoperative period was were also ultrastructurally identical. Clas- unremarkable and the patient is currently sical malignant fibrothecomas are said to undergoing chemotherapy. show four or more mitotic figures per 10 high power fields (HPF).
    [Show full text]
  • Collision Glial Neoplasms Arising in an Ovarian Mature Cystic Teratoma: a Rare Event
    Hindawi Case Reports in Pathology Volume 2020, Article ID 7568671, 4 pages https://doi.org/10.1155/2020/7568671 Case Report Collision Glial Neoplasms Arising in an Ovarian Mature Cystic Teratoma: A Rare Event Abdelrazak Meliti ,1,2 Bayan Hafiz,1 Haneen Al-Maghrabi ,1 and Abdulrahim Gari3 1Department of Anatomic Pathology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia 2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada 3Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia Correspondence should be addressed to Abdelrazak Meliti; [email protected] Received 26 September 2019; Accepted 27 January 2020; Published 3 February 2020 Academic Editor: Dimosthenis Miliaras Copyright © 2020 Abdelrazak Meliti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Germ cell neoplasms represent around 20% of all ovarian tumors. They most frequently affect children and young adults. Mature cystic teratoma is a common benign ovarian neoplasm comprising about 95% and is made up of all three germ cell embryonic layers. By definition, mature cystic teratoma may be derived from any of the three germ cell lines. On the other hand, immature teratomas contain primitive neuroepithelial elements. However, it is quite uncommon in the English literature to have a neuroepithelial glial neoplasm arising in a mature cystic teratoma of an adolescent. Interestingly enough, all published cases described a single type of glial neoplasm arising in mature ovarian teratoma.
    [Show full text]
  • Production of a Monoclonal Antibody Specific for Seminomas And
    Proc. Nati. Acad. Sci. USA Vol. 83, pp. 5291-5295, July 1986 Medical Sciences Production of a monoclonal antibody specific for seminomas and dysgerminomas (testicular and ovarian tumors/oncofetal antigen/glycoprotein/Mr 40,000 cell surface protein/immunoperoxidase) DENIS BAILEY*, REUBEN BAUMALt, JOHN LAWt, KATHERINE SHELDONt, PAUL KANNAMPUZHAt, MICHAEL STRATIS*, HARRIETTE KAHN§, AND ALEXANDER MARKSt *Departments of Pathology, Toronto General Hospital, MSG 1L7, tThe Hospital for Sick Children, M5G 1X8, tBanting and Best Department of Medical Research, University of Toronto, M5G 1L6, and §Women's College Hospital, Toronto, ON, Canada, M5S 1B2 Communicated by J. Tuzo Wilson, March 14, 1986 ABSTRACT A monoclonal antibody (M2A, IgG2a) was cultures in minimal essential medium alpha (Flow Laborato- produced against a cultured human ovarian epithelial adeno- ries) supplemented with 7% fetal bovine serum and 2 mM carcinoma cell line, HEY. Monoclonal antibody M2A reacted glutamine. with a glycoprotein of molecular weight 40,000 on the surface Human Normal Tissues and Tumors. Various normal tis- of HEY cells. The affinity constant of the monoclonal antibody sues and tumors were obtained from surgical biopsy speci- M2A for HEY cells was 109 M-1, and the number of binding mens processed in the departments of pathology at The sites on HEY cells was 2 x 104 per cell. The monoclonal Hospital for Sick Children, Toronto General Hospital and antibody produced positive immunoperoxidase staining offetal Women's College Hospital. (but not adult) testis and ofseminomas and dysgerminomas but Production of mAb. Eight-week-old female BALB/c mice did not stain various normal adult tissues or other gonadal or (Canadian Breeding Laboratories, Montreal, PQ) were im- extragonadal tumors.
    [Show full text]
  • Second Revised Proposed Regulation of the State
    SECOND REVISED PROPOSED REGULATION OF THE STATE BOARD OF HEALTH LCB File No. R057-16 February 5, 2018 EXPLANATION – Matter in italics is new; matter in brackets [omitted material] is material to be omitted. AUTHORITY: §§1, 2, 4-9 and 11-15, NRS 457.065 and 457.240; §3, NRS 457.065 and 457.250; §10, NRS 457.065; §16, NRS 439.150, 457.065, 457.250 and 457.260. A REGULATION relating to cancer; revising provisions relating to certain publications adopted by reference by the State Board of Health; revising provisions governing the system for reporting information on cancer and other neoplasms established and maintained by the Chief Medical Officer; establishing the amount and the procedure for the imposition of certain administrative penalties by the Division of Public and Behavioral Health of the Department of Health and Human Services; and providing other matters properly relating thereto. Legislative Counsel’s Digest: Existing law defines the term “cancer” to mean “all malignant neoplasms, regardless of the tissue of origin, including malignant lymphoma and leukemia” and, before the 78th Legislative Session, required the reporting of incidences of cancer. (NRS 457.020, 457.230) Pursuant to Assembly Bill No. 42 of the 78th Legislative Session, the State Board of Health is: (1) authorized to require the reporting of incidences of neoplasms other than cancer, in addition to incidences of cancer, to the system for reporting such information established and maintained by the Chief Medical Officer; and (2) required to establish an administrative penalty to impose against any person who violates certain provisions which govern the abstracting of records of a health care facility relating to the neoplasms the Board requires to be reported.
    [Show full text]
  • Benign Brenner Tumor of Ovary - a Rare Case Report
    Nehal Tiwari, Hardik Gandhi. Benign Brenner tumor of ovary - A rare case report. IAIM, 2018; 5(10): 153-156. Case Report Benign Brenner tumor of ovary - A rare case report Nehal Tiwari1*, Hardik Gandhi1 1Resident Doctor, Pathology Department, SBKS MI & RC, Sumandeep Vidyapeeth, Vadodara, Gujarat, India *Corresponding author email: [email protected] International Archives of Integrated Medicine, Vol. 5, Issue 10, October, 2018. Copy right © 2018, IAIM, All Rights Reserved. Available online at http://iaimjournal.com/ ISSN: 2394-0026 (P) ISSN: 2394-0034 (O) Received on: 12-09-2018 Accepted on: 17-09-2018 Source of support: Nil Conflict of interest: None declared. How to cite this article: Nehal Tiwari, Hardik Gandhi. Benign Brenner tumor of ovary - A rare case report. IAIM, 2018; 5(10): 153-156. Abstract Ovarian tumors are common forms of neoplasia in women and it accounts for about 30.0% of female genital cancers. Brenner tumors are subgroup of transitional cell tumors. Benign Brenner tumors are usually unilateral, small and solid. But in our case the tumor was very huge though showing all features of benign Brenner tumor on histopathological examination. For the diagnosis of benign Brenner tumor, radiological investigations are not a reliable tool. Therefore histopathological examination remains gold standard method for final diagnosis of this entity. This case report of large benign Brenner tumor is presented here because of its rarity. Key words Benign Brenner tumor, Rare, Ovarian tumors, Histopathological examination. Introduction association with serous and mucinous The ovarian lesion constitutes the major burden cystadenomas is up to 30% [1, 2]. USG and in gynecology practices due to anatomical computed tomography, both the techniques are location of the tumor and also due to the fact that less sensitive method for the diagnosis because these tumors may remain asymptomatic for a of its nonspecific appearance.
    [Show full text]
  • Gynecological Tumors in Mulibrey Nanism and Role for RING Finger Protein TRIM37 in the Pathogenesis of Ovarian Fibrothecomas
    Modern Pathology (2009) 22, 570–578 & 2009 USCAP, Inc All rights reserved 0893-3952/09 $32.00 www.modernpathology.org Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas Susann Karlberg1,2, Marita Lipsanen-Nyman2, Heini Lassus1, Jukka Kallija¨rvi3,4,5, Anna-Elina Lehesjoki3,4,5 and Ralf Butzow1,6 1Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki, Helsinki, Finland; 2Children’s Hospital, University of Helsinki, Helsinki, Finland; 3Folkha¨lsan Institute of Genetics, Helsinki, Finland; 4Department of Medical Genetics, University of Helsinki, Helsinki, Finland; 5Neuroscience Center, University of Helsinki, Helsinki, Finland and 6Department of Pathology, University of Helsinki, Helsinki, Finland Mulibrey nanism is an autosomal recessive growth disorder caused by mutations in the TRIM37 gene encoding a protein of unknown function. More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord–stromal origin. In this work, we characterize the gynecological tumors of female patients with Mulibrey nanism in detail. In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma. To investigate the possible involvement of TRIM37 alterations in the pathogenesis of sporadic fibrothecomas, we analyzed the TRIM37 cDNA for mutations and alternatively spliced transcripts and TRIM37 expression in fibrothecomas of women without Mulibrey nanism. No mutations in the open-reading frame of TRIM37 were detected. Two alternatively spliced variants were found, one lacking exon 23 and one exon 2.
    [Show full text]
  • Ovarian Sex Cord-Stromal Tumors
    Review Int J Gynecol Cancer: first published as 10.1136/ijgc-2020-002018 on 7 January 2021. Downloaded from Ovarian sex cord- stromal tumors: an update INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER Original research Editorials Joint statement Society statement on clinical features, molecular changes, Meeting summary Review articles Consensus statement Clinical trial Case study Video articles Educational video lecture and management Images Pathology archives Corners of the world Commentary Letters ijgc.bmj.com Rehab Al Harbi,1 Iain A McNeish,2 Mona El- Bahrawy1,3 1Department of Metabolism, ABSTRACT cord tumors with annular tubules, arise from primi- Digestion, and Reproduction, 7 Sex cord stromal- tumors are rare tumors of the ovary that tive sex cord cells. Mixed sex cord- stromal tumors Imperial College London, include Sertoli–Leydig cell tumors and sex cord- London, UK include numerous tumor subtypes of variable histological 2Department of Surgery and features and biological behavior. Surgery is the main stromal tumors that have not otherwise been spec- 7 Cancer, Imperial College therapeutic modality for the management of these ified. London, London, UK tumors, while chemotherapy and hormonal therapy may Sex cord- stromal tumors may present with an 3 Department of Pathology, be used in some patients with progressive and recurrent adnexal mass, abdominal distention, and abdom- Faculty of Medicine, University tumors. Several studies investigated molecular changes inal pain.1 Unlike epithelial and germ cell tumors, of Alexandria, Alexandria, Egypt in the different tumor types. Understanding molecular some sex cord- stromal tumors have clinical signs of changes underlying the development and progression of hormone production, including menstrual changes, Correspondence to sex cord-stromal tumors provides valuable information 1 Professor Mona El-Bahra wy, for diagnostic and prognostic biomarkers and potential precocious puberty, hirsutism, and/or virilization.
    [Show full text]
  • Perspectives on Testicular Sex Cord-Stromal Tumors and Those Composed of Both Germ Cells
    ACCEPTED MANUSCRIPT Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms Lawrence M. Roth MD*1, Bingjian Lyu MD3, Liang Cheng MD*1,2 Department of Pathology and Laboratory Medicine1and Urology2, Indiana University School of Medicine, Indianapolis, IN 46202; Department of Pathology3, Women’s Hospital, School of Medicine, Zhejiang University, 310003, China. Running Head: Perspectives on testicular sex cord-stromal tumors Keywords: Testis; Ovary; Sex cord-stromal tumors; Gonadoblastoma; Mixed germ cell- sex cord stromal tumor; Tumorigenesis. Address correspondence to: Lawrence M. Roth MD, Department of Pathology, Indiana University School of Medicine, Van Nuys Medical Science Building 128, 635 Barnhill Drive, Indianapolis, IN 46202, USA; [email protected] or Liang Cheng, MD, Department of Pathology, Indiana UniversityACCEPTED School of Medicine, Indianapolis, MANUSCRIPT IN 46202; [email protected] Disclosures: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. No conflict of interest exists. _________________________________________________________________________________ This is the author's manuscript of the article published in final edited form as: Roth, L. M., Lyu, B., & Cheng, L. (2017). Perspectives on testicular sex cord-stromal tumors and those composed of both germ cells and sex cord-stromal derivatives with a comparison to corresponding ovarian neoplasms. Human Pathology. https://doi.org/10.1016/j.humpath.2017.04.009 ACCEPTED MANUSCRIPT Highlights - Sex cord-stromal tumors are the second most frequent category of testicular neoplasms. - They account for approximately 2-5% of testicular neoplasms in adults. - Both genetic and epigenetic factors account for their differences from ovarian SCSTs.
    [Show full text]
  • Section of Radiology President-J
    Sectional of the Medicine Vol. 48 page 1 Proceedings.1 h RoyalLy&SceyoSociey of 721 Section of Radiology President-J. F. BROMLEY, O.B.E., F.R.C.P. [January 21, 1955] DISCUSSION ON THE PATHOLOGY AND TREATMENT OF FUNCTIONING OVARIAN TIJMOURS AND OTHER UNUSUAL GROWTHS OF TIHE OVARY Dr. C. W. Taylor (Director of Pathology, The Birmingham and Midland Hospitals for Women, United Birmingham Hospitals): The Pathology and Histogenesis ofSpecial Ovarian Tumours The ovary is a common site of neoplasm. Certain primary tumours of the sex gland are associated with endocrine abnormalities-so-called "Functioning ovarian tumours". The effects are mainly of feminizing or masculinizing type. Tumours of similar histogenesis, though not associated with endocrine dysfunction, and tumours originally, but wrongly, thought to be of functional type, are usually discussed in the same context under the heading "Special and functioning ovarian tumours". Incidence.-From a ten-year study of cases of primary ovarian neoplasm at the Women's Hospital, Birmingham, the following figures were obtained (Taylor, 1950): Simple neoplasm .. 600 74-2% Malignant neoplasm .. 171 21-2% "Special" group .. 37 4 6% Total 808 The tumours classified under this "Special" group were: Granulosa cell tumour .. .. .. 18 Theca cell tumour .. .. .. 7 Arrhenoblastoma .. .. .. 3 Dysgerminoma .. .. .. .. 3 Brenner tumour .. .. .. .. 6 Total 37 The special group oftumours under consideration were not classified as simple or malignant at that time. The cases have been followed up and the findings will be referred to later by Dr. Blomfield. The theca cell and Brenner tumours are essentially benign. Histological examination of the others will not, in many cases, give an answer to the degree of clinical malignancy.
    [Show full text]
  • (NCCN Guidelines®) Ovarian Cancer
    ® NCCN NCCN Guidelines Index Ovarian Cancer TOC Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 2.2013 NCCN.org NCCN Guidelines for Patients™ are available at www.nccn.com. Continue Version 2.2013, 06/13/13 © National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. ® NCCN NCCN Guidelines Version 2.2013 Panel Members NCCN Guidelines Index Ovarian Cancer TOC Ovarian Cancer Discussion * Robert J. Morgan, Jr., MD/Chair ‡ * Ardeshir Hakam, MD ¹ * Matthew A. Powell, MD W City of Hope Comprehensive Cancer Center Moffitt Cancer Center Siteman Cancer Center at Barnes- Jewish Hospital and Washington * Ronald D. Alvarez, MD W * Laura J. Havrilesky, MD W University School of Medicine University of Alabama at Birmingham Duke Cancer Institute Comprehensive Cancer Center Steven W. Remmenga, MD W Carolyn Johnston, MD W UNMC Eppley Cancer Center at * Deborah K. Armstrong, MD † University of Michigan The Nebraska Medical Center The Sidney Kimmel Comprehensive Comprehensive Cancer Center Cancer Center at Johns Hopkins Paul Sabbatini, MD †Þ * Shashikant Lele, MD W Memorial Sloan-Kettering Cancer Center Robert A. Burger, MD W Roswell Park Cancer Institute Fox Chase Cancer Center Joseph T. Santoso, MD W Lainie Martin, MD † St. Jude Children’s Research Hospital/ Lee-may Chen, MD W Fox Chase Cancer Center University of Tennessee Cancer Institute UCSF Helen Diller Family Comprehensive Cancer Center * Ursula A. Matulonis, MD † *Julian C. Schink, MD W Dana-Farber/Brigham and Women’s Robert H.
    [Show full text]
  • A Case Report of Ovarian Fibrothecoma in a Premenopausal Women with Recurrent Menorrhagia
    Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia Open Access Macedonian Journal of Medical Sciences. 2020 Jul 20; 8(C):101-105. https://doi.org/10.3889/oamjms.2020.4176 eISSN: 1857-9655 Category: C - Case Reports Section: Case Reports in Gynecology and Obstetrics A Case Report of Ovarian Fibrothecoma in a Premenopausal Women with Recurrent Menorrhagia Meral Rexhepi1,2*, Elizabeta Trajkovska3, Hysni Ismaili2, Majlinda Azemi4 1Department of Gynecology and Obstetrics, Clinical Hospital, Tetovo, Republic of Macedonia; 2Faculty of Medical Sciences, University of Tetovo, Republic of Macedonia; 3Department of Pathology, Clinical Hospital, Tetovo, Republic of Macedonia; 4University Clinic of Gynaecology and Obstetrics, University “Ss Cyril and Methodius”, Skopje, Republic of Macedonia Abstract Edited by: Igor Spiroski BACKGROUND: Ovarian fibrothecoma is a rare, benign, sex cord-stromal neoplasm, with a typically unilateral Citation: Rexhepi M, Trajkovska E, Ismaili H, Azemi M. A Case Report of Ovarian Fibrothecoma in a location in the ovary, characterized by mixed features of both fibroma and thecoma. Ovarian fibrothecoma is Premenopausal Women with Recurrent Menorrhagia. uncommon tumor of gonadal stromal cell origin accounting for 3-4% of all ovarian tumours. Open Access Maced J Med Sci. 2020 Jul 20; 8(C):101-105. https://doi.org/10.3889/oamjms.2020.4176 CASE PRESENTATION: We presented a rare case of a 46-year-old patient with recurrent menorrhagia in the Keywords: Ovarian granulosa cell tumor; Fibrothecoma; Endometrial hyperplasia past two years with no previous medical, surgical or gynecological history. She underwent two times curettage *Correspondence: Meral Rexhepi, Department procedures. At the admission to hospital ultrasonography showed a homogenous solid right ovarian mass of size of Gynecology and Obstetrics, Clinical Hospital, 2.5 cm x 3.5 cm.
    [Show full text]